Laleh Abbassi

Laleh Abbassi

Auto-generated profile, based on publicly available information

Laleh Abbassi

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
JDJulien Dilly
Julien Dilly
MHMegan T. Hoffman
Megan T. Hoffman
LALaleh Abbassi
Laleh Abbassi
ZLZiyue Li
Ziyue Li
FPfrancesca Paradiso
francesca Paradiso
AAAndrew J. Aguirre
Andrew J. Aguirre
KRAS inhibitors demonstrate clinical efficacy in pancreatic ductal adenocarcinoma (PDAC); however, resistance is common. Among patients with KRASG12C-mutant PDAC treated with adagrasib or sotorasib, mutations in PIK3CA and KRAS, and amplifications of KRASG12C, MYC, MET, EGFR, and CDK6 emerged at acquired resistance. In PDAC cell lines and organoid models treated with the KRASG12D inhibitor MRTX1133, epithelial-to-mesenchymal transition and PI3K-AKT-mTOR signaling associate with resistance to therapy. MRTX1133 treatment of the KrasLSL-G12D/+; Trp53LSL-R172H/+; p48-Cre (KPC) mouse model yielded deep tumor regressions, but drug resistance ultimately emerged, accompanied by amplifications of Kras, Yap1, Myc, Cdk6, and Abcb1a/b, and co-evolution of drug-resistant transcriptional programs. Moreover, in KPC and PDX models, mesenchymal and basal-like cell states displayed increased response to KRAS inhibition compared to the classical state. Combination treatment with KRASG12D inhibition and chemotherapy significantly improved tumor control in PDAC mouse models. Collectively, these data elucidate co-evolving resistance mechanisms to KRAS inhibition and support multiple combination therapy strategies. Significance: Acquired resistance may limit the impact of KRAS inhibition in patients with PDAC. Using clinical samples and multiple preclinical models, we define heterogeneous genetic and non-genetic mechanisms of resistance to KRAS inhibition that may guide combination therapy approaches to improve the efficacy and durability of these promising therapies for patients. See related commentary by Marasco and Misale, p. 2018

17 June 2026
Verified
Other
Open access
JDJulien Dilly
Julien Dilly
MHMegan T. Hoffman
Megan T. Hoffman
LALaleh Abbassi
Laleh Abbassi
ZLZiyue Li
Ziyue Li
FPfrancesca Paradiso
francesca Paradiso
AAAndrew J. Aguirre
Andrew J. Aguirre
Genetic and copy number variants at resistance to adagrasib or sotorasib across the novel cohort of PDAC and GI cancer patients.

17 June 2026
Verified
Other
Open access
JDJulien Dilly
Julien Dilly
MHMegan T. Hoffman
Megan T. Hoffman
LALaleh Abbassi
Laleh Abbassi
ZLZiyue Li
Ziyue Li
FPfrancesca Paradiso
francesca Paradiso
AAAndrew J. Aguirre
Andrew J. Aguirre
Characterization of acquired resistance to KRASG12C inhibition across studies and cancer types.

17 June 2026
Verified
Other
Open access
JDJulien Dilly
Julien Dilly
MHMegan T. Hoffman
Megan T. Hoffman
LALaleh Abbassi
Laleh Abbassi
ZLZiyue Li
Ziyue Li
FPfrancesca Paradiso
francesca Paradiso
AAAndrew J. Aguirre
Andrew J. Aguirre
Supplemental Table 5A: Drug sensitivity metrics from MRTX1133-treated KRASG12D patient-derived organoids. Supplemental Table 5B: MRTX1133 dose response across KRASG12D mutated patient-derived organoids.

17 June 2026
Verified
Other
Open access
JDJulien Dilly
Julien Dilly
MHMegan T. Hoffman
Megan T. Hoffman
LALaleh Abbassi
Laleh Abbassi
ZLZiyue Li
Ziyue Li
FPfrancesca Paradiso
francesca Paradiso
AAAndrew J. Aguirre
Andrew J. Aguirre
List of reagents and antibodies used in the study

17 June 2026
Verified
Other
Open access
JDJulien Dilly
Julien Dilly
MHMegan T. Hoffman
Megan T. Hoffman
LALaleh Abbassi
Laleh Abbassi
ZLZiyue Li
Ziyue Li
FPfrancesca Paradiso
francesca Paradiso
AAAndrew J. Aguirre
Andrew J. Aguirre
Supplemental Table 4A: Differential gene expression analysis between MRTX1133 sensitive and resistant KRASG12D cell lines. Supplemental Table 4B: Analysis of Copy number and RPPA datasets between MRTX1133 sensitive and resistant KRASG12D cell lines.